Michelle Irvin

878 total citations
17 papers, 665 citations indexed

About

Michelle Irvin is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Michelle Irvin has authored 17 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hepatology, 14 papers in Infectious Diseases and 14 papers in Epidemiology. Recurrent topics in Michelle Irvin's work include Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (14 papers) and Hepatitis B Virus Studies (10 papers). Michelle Irvin is often cited by papers focused on Hepatitis C virus research (15 papers), HIV/AIDS drug development and treatment (14 papers) and Hepatitis B Virus Studies (10 papers). Michelle Irvin collaborates with scholars based in United States and Japan. Michelle Irvin's co-authors include Thomas Reisch, Preethi Krishnan, Jill Beyer, Rakesh Tripathi, Christine A. Collins, Gretja Schnell, Tatyana Dekhtyar, Edward Tam, Teresa I. Ng and Lois Larsen and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and Journal of Hepatology.

In The Last Decade

Michelle Irvin

17 papers receiving 654 citations

Peers

Countries citing papers authored by Michelle Irvin

Since Specialization

Citations

This map shows the geographic impact of Michelle Irvin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Irvin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Irvin more than expected).

Fields of papers citing papers by Michelle Irvin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Irvin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Irvin. The network helps show where Michelle Irvin may publish in the future.

Co-authorship network of co-authors of Michelle Irvin

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Irvin. A scholar is included among the top collaborators of Michelle Irvin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Irvin. Michelle Irvin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors 2020 ·Bioorganic & Medicinal Chemistry Letters ·John T. Randolph, Tongmei Li, A. Chris Krueger, H. Robin Heyman, Hui-Ju Chen, Daniel A.J. Bow, (unknown), Vincent Peterkin, Robert A. Carr, DeAnne Stolarik, Tatyana Dekhtyar, Michelle Irvin, Preethi Krishnan, Rolf Wagner, David A. DeGoey	3
2	Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir 2018 ·PLoS ONE ·Gretja Schnell, Preethi Krishnan, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Liangjun Lu, Teresa I. Ng, Wangang Xie, Edward Tam, Christine A. Collins	10
3	Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection 2018 ·Viruses ·Teresa I. Ng, Edward Tam, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Liangjun Lu, Armen Asatryan, Andrew Campbell, Betty Yao, Sandra Lovell, Federico Mensa, Eric Lawitz, Jens Kort, Christine A. Collins	3
4	Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials 2018 ·Antimicrobial Agents and Chemotherapy ·Preethi Krishnan, Edward Tam, Gretja Schnell, Rakesh Tripathi, Teresa I. Ng, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Lois Larsen, Federico Mensa, Christine A. Collins	58
5	Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4‐infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir 2018 ·Journal of Viral Hepatitis ·Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Preethi Krishnan, Tatyana Dekhtyar, Michelle Irvin, Coleen Hall, Yao Yu, Niloufar Mobashery, Rebecca Redman, (unknown), Catherine A. Collins	3
6	Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials 2017 ·Journal of Hepatology ·Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Teresa I. Ng, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Wenhui Xie, Lois Larsen, Federico Mensa, (unknown), Catherine A. Collins	23
7	Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan 2017 ·Antimicrobial Agents and Chemotherapy ·Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Tatyana Dekhtyar, Michelle Irvin, Wangang Xie, Bo Fu, Margaret Burroughs, Rebecca Redman, Hiromitsu Kumada, Kazuaki Chayama, Christine A. Collins, Edward Tam	36
8	Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes 2017 ·Journal of Hepatology ·Teresa I. Ng, Liangjun Lu, Thomas Reisch, Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, (unknown), Catherine A. Collins	5
9	In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir 2017 ·Antimicrobial Agents and Chemotherapy ·Teresa I. Ng, Rakesh Tripathi, Thomas Reisch, Liangjun Lu, Timothy Middleton, Todd A. Hopkins, Ron Pithawalla, Michelle Irvin, Tatyana Dekhtyar, Preethi Krishnan, Gretja Schnell, Jill Beyer, Keith F. McDaniel, Jun Ma, Guoqiang Wang, Lijuan Jiang, Yat Sun Or, Dale J. Kempf, Edward Tam, Christine A. Collins	57
10	Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir 2017 ·Journal of Medical Virology ·Gretja Schnell, Rakesh Tripathi, Preethi Krishnan, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Carolyn M. Setze, Lino Rodrigues, Katia Alves, Margaret Burroughs, Rebecca Redman, Kazuaki Chayama, Hiromitsu Kumada, Christine A. Collins, Edward Tam	11
11	Resistance analysis in the MAGELLAN-1 Study (Part 2): glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors 2017 ·Journal of Hepatology ·(unknown), Preethi Krishnan, Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Michelle Irvin, Tatyana Dekhtyar, Teresa I. Ng, Lei Yao, Armen Asatryan, Federico Mensa, Catherine A. Collins	6
12	In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir 2017 ·Antimicrobial Agents and Chemotherapy ·Teresa I. Ng, Preethi Krishnan, Edward Tam, Warren M. Kati, Gretja Schnell, Jill Beyer, Thomas Reisch, Liangjun Lu, Tatyana Dekhtyar, Michelle Irvin, Rakesh Tripathi, Clarence J. Maring, John T. Randolph, Rolf Wagner, Christine A. Collins	92
13	Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir 2015 ·Antimicrobial Agents and Chemotherapy ·Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Michelle Irvin, Wangang Xie, Lois Larsen, Daniel E. Cohen, Thomas Podsadecki, Edward Tam, Christine A. Collins	77
14	O057 : Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens 2015 ·Journal of Hepatology ·Preethi Krishnan, Rakesh Tripathi, Gretja Schnell, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Wenhui Xie, Lois Larsen, Thomas Podsadecki, (unknown), Catherine A. Collins	71
15	In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450 2014 ·Antimicrobial Agents and Chemotherapy ·Edward Tam, Rakesh Tripathi, Daniel E. Cohen, (unknown), Tatyana Dekhtyar, Liangjun Lu, Thomas Reisch, Michelle Irvin, Todd A. Hopkins, Ron Pithawalla, Timothy Middleton, Teresa I. Ng, Keith F. McDaniel, Yat Sun Or, Rajeev Menon, Dale J. Kempf, Akhteruzzaman Molla, Christine A. Collins	102
16	In Vitro Activity and Resistance Profile of Dasabuvir, a Nonnucleoside Hepatitis C Virus Polymerase Inhibitor 2014 ·Antimicrobial Agents and Chemotherapy ·Warren M. Kati, Gennadiy Koev, Michelle Irvin, Jill Beyer, Yaya Liu, Preethi Krishnan, Thomas Reisch, Rubina Mondal, Rolf Wagner, Akhteruzzaman Molla, Clarence J. Maring, Christine A. Collins	88
17	Phenotypic Analysis of T-Cells in Extensive Alopecia Areata Scalp Suggests Partial Tolerance 2005 ·Journal of Investigative Dermatology ·Matthew J. Deeths, Bart T. Endrizzi, Michelle Irvin, (unknown), Marna E. Ericson, Maria Hordinsky	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact